Gestor Editorial

Nuevo Usuario
Revisiones en Cáncer 00093 / http://dx.doi.org/10.20960/revcancer.00093
Resumen| PDF

Revisión

Diagnóstico por imagen del cáncer epitelial de ovario

Julio Fernández Mata, Clara M. Romero Martínez, Paula Molina Vigara, Paula Orenes Castrillo, Mar Jiménez de la Peña

Prepublicado: 2024-11-08

Logo Descargas   Número de descargas: 344      Logo Visitas   Número de visitas: 51      Citas   Citas: 0

Compártelo:


El cáncer de ovario es una patología agresiva, generalmente de diagnóstico tardío en fases avanzadas de la enfermedad, dada su presentación clínica insidiosa. Las pruebas de imagen son exploraciones claves en el estudio integral del cáncer de ovario, que influyen significativamente en el manejo y en el pronóstico de estos pacientes. La evaluación de las lesiones ováricas suele llevarse a cabo inicialmente mediante ecografía y posteriormente, mediante resonancia magnética (RM) multiparamétrica, que permiten clasificarlas según el riesgo de malignidad mediante sistemas estandarizados de descripción (O-RADS). Por otro lado, la tomografía computarizada (TAC) y la RM son las pruebas más utilizadas en la valoración de la afectación peritoneal para el diagnóstico y la estadificación, en la que es recomendable recoger el índice de carcinomatosis peritoneal. Sin embargo, para el análisis de respuesta al tratamiento y la detección de recidivas, la tomografía de emisión de positrones fusionada con TAC (PET-TAC) sigue siendo la exploración de referencia..

Palabras Clave: Carcinoma epitelial de ovario. Imagen-RM. Imagen-difusión. Imagen-PET. O-RADS.



SEOM. Sistema. Cáncer de ovario; 2022 [citado el 30 de junio de 2024]. Disponible en: https://seom.org/info-sobre-el-cancer/ovario?start=1
Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 2002;22(6):1305-25.
DOI: 10.1148/rg.226025033
Coleman RL, Liu J, Matsuo K, Thaker PH, Westin SN, Sood AK. Carcinoma of the ovaries and Fallopian tubes. En: Abeloff’s Clinical Oncology. Elsevier; 2020. p. 1525-43.e7.
DOI: 10.1016/B978-0-323-47674-4.00086-4
American College of Radiology. Ovarian-Adnexal Reporting & Data System (O-RADS). Retrieved from acr.org; 2023.
Andreotti RF, Timmerman D, Strachowski LM, Froyman W, Benacerraf BR, Bennett GL, et al. O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology 2018;289(3):868-84.
Strachowski LM, Jha P, Phillips CH, Blanchette Porter MM, Froyman W, Glanc P, et al. O-RADS US v2022: An update from the American college of radiology’s ovarian-adnexal reporting and data system US committee. Radiology 2023;308(3).
DOI: 10.1148/radiol.230685
Wang PS, Schoeck OG, Horrow MM. Benign-appearing incidental adnexal cysts at US, CT, and MRI: Putting the ACR, O-RADS, and SRU guidelines all together. Radiographics 2022;42(2):609-24.
DOI: 10.1148/rg.210091
Anbarasu S, Anbarasu A. Cancer-biomarkers associated with sex hormone receptors and recent therapeutic advancements: a comprehensive review. Med Oncol 2023;40(6).
DOI: 10.1007/s12032-023-02044-3
Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: A comprehensive review. Cancers (Basel) 2020;12(12):3730.
DOI: 10.3390/cancers12123730
Ahmed AA, Abdou AM. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels. Curr Probl Cancer 2019;43(5):450-60.
DOI: 10.1016/j.currproblcancer.2018.12.004
Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol 2010;194(2):311-21.
DOI: 10.2214/AJR.09.3522
Tempany C, Zou K, Silverman S, Brown D, Kurtz A, McNeil B. Staging of advanced ovarian cancer: Comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology 2000;215:761-7.
DOI: 10.1148/radiology.215.3.r00jn25761
Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005;96:301-6.
DOI: 10.1016/j.ygyno.2004.06.054
Bristow RE, Duska LR, Lambrou NC, Fishman EK, O’Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:1532-40.
DOI: 10.1002/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A
Nougaret S, Addley HC, Colombo PE, Fujii S, Al Sharif SS, Tirumani S, et al. Ovarian carcinomatosis: How the radiologist can help plan the surgical approach. Radiographics 2012;32(6):775-800.
DOI: 10.1148/rg.326125511
Elsherif SB, Zheng S, Ganeshan D, Iyer R, Wei W, Bhosale PR. Does dual-energy CT differentiate benign and malignant ovarian tumours? Clin Radiol 2020;75:606-14.
DOI: 10.1016/j.crad.2020.03.006
Benveniste AP, De Castro Faria S, Broering G, Ganeshan DM, Tamm EP, Iyer RB, et al. Potential Application of Dual-Energy CT in Gynecologic Cancer: Initial Experience. Am J Roentgenol 2017;208:695-705.
DOI: 10.2214/AJR.16.16227
Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, et al. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecol Oncol 2019;152:235-42.
DOI: 10.1016/j.ygyno.2018.11.008
Sadowski EA, Thomassin-Naggara I, Rockall A, Maturen KE, Forstner R, Jha P, et al. O-RADS MRI risk stratification system: Guide for assessing adnexal lesions from the ACR O-RADS committee. Radiology 2022;303(1):35-47.
DOI: 10.1148/radiol.204371
Hricak H, Chen M, Coakley FV, Kinkel K, Yu KK, Sica G, et al. Complex adnexal masses:detection and characterization with MR imaging-multivariate analysis. Radiology 2000;214:39-46.
DOI: 10.1148/radiology.214.1.r00ja3939
Bozkurt M, Doganay S, Kantarci M, Yalcin A, Eren S, Atamanalp SS, et al. Comparison of peritoneal tumor imaging using conventional MR imaging and diffusion-weighted MR imaging with different b values. Eur J Radiol 2011;80:224-8.
DOI: 10.1016/j.ejrad.2010.06.004
Wei M, Bo F, Cao H, Zhou W, Shan W, Bai G. Diagnostic performance of dynamic contrast-enhanced magnetic resonance imaging for malignant ovarian tumors: a systematic review and meta-analysis. Acta Radiol 2021;62(7):966-78.
DOI: 10.1177/0284185120944916
Oh JW, Rha SE, Oh SN, Park MY, Byun JY, Lee A. Diffusion- weighted MRI of epithelial ovarian cancers: Correlation of apparent diffusion coefficient values with histologic grade and surgical stage. Eur J Radiol 2015;84(4):590-5.
DOI: 10.1016/j.ejrad.2015.01.005
Crombé A, Gauquelin L, Nougaret S, Chicart M, Pulido M, Floquet A, et al. Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy. Diagnostic and Interventional Imaging 2021;102(10):629-39.
DOI: 10.1016/j.diii.2021.05.007
Fujii S, Matsusue E, Kanasaki Y, Kanamori Y, Nakanishi J, Sugihara S, et al. Detection of peritoneal dissemination in gynecological malignancy: Evaluation by diffusion-weighted MR imaging. Eur Radiol 2008;18:18-23.
DOI: 10.1007/s00330-007-0732-9
Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 2015;22:1708-15.
DOI: 10.1245/s10434-014-4041-7
Tempany C, Zou K, Silverman S, Brown D, Kurtz A, McNeil B. Staging of advanced ovarian cancer: Comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology 2000;215:761-7.
DOI: 10.1148/radiology.215.3.r00jn25761
Ricke J, Sehouli J, Hach C, Hänninen EL, Lichtenegger W, Felix R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 2003;13:943-9.
DOI: 10.1007/s00330-002-1712-8
Rizzo S, De Piano F, Buscarino V, Pagan E, Bagnardi V, Zanagnolo V, et al. Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. Eur J Radiol 2020;123:108786.
DOI: 10.1016/j.ejrad.2019.108786
Ledermann JA, Raja FA, Fotopoulou C, González-Martín A, Colombo N, Sessa C. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl.6):vi24-vi32.
DOI: 10.1093/annonc/mdt333
Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: Initial observations. Radiographics 2004;24(1):209-23.
DOI: 10.1148/rg.241035078
Pfannenberg C, Königsrainer I, Aschoff P, Oksüz M, Zieker D, Beckert S, et al. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2009;16:1295-303.
DOI: 10.1245/s10434-009-0387-7
Kim S-K, Kang KW, Roh JW, Sim JS, Lee ES, Park S-Y. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging 2005;32(7):757-63.
DOI: 10.1007/s00259-005-1771-6
Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging 2017;44(6):1079-91.
DOI: 10.1007/s00259-017-3638-z
Tentes AAK, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: A prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003;29:69-73.
DOI: 10.1053/ejso.2002.1380
Rosendahl M, Harter P, Bjørn SF, Høgdall C. Specific Regions, rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer. Int J Gynecol Cancer 2018;28(2):316-22.
DOI: 10.1097/IGC.0000000000001173
Avesani Arshad M, Lu H, Fotopoulou C, Cannone F, Melotti R, Aboagye E, et al. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival. Radiol Med 2020;125(8):770-6.
DOI: 10.1007/s11547-020-01170-6
Mikkelsen MS, Petersen LK, Blaakaer J, Marinovskij E, Rosenkilde M, Andersen G, et al. Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductive surgery for advanced stage epithelial ovarian cancer. Eur J Surg Oncol 2021;47(8):2134-41.
DOI: 10.1016/j.ejso.2021.03.239
Mitchell DG, Javitt MC, Glanc P, Bennett GL, Brown DL, Dubinsky T, et al. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol 2013;10(11):822-7.
DOI: 10.1016/j.jacr.2013.07.017
Castellucci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 2007;28(8):589-95.
DOI: 10.1097/MNM.0b013e3281afa256
Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging 2008;35(10):1912-20.
DOI: 10.1007/s00259-008-0890-2
Yoshida Y, Kurokawa T, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004;182(1):227-33.
DOI: 10.2214/ajr.182.1.1820227
Mitchell DG, Javitt MC, Glanc P, Bennett GL, Brown DL, Dubinsky T, et al. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol 2013;10(11):822-7.
DOI: 10.1016/j.jacr.2013.07.017
Nougaret S, Sadowski E, Lakhman Y, Rousset P, Lahaye M, Worley M, et al. The BUMPy road of peritoneal metastases in ovarian cancer. Diagn Interv Imaging 2022;103:448-59.
DOI: 10.1016/j.diii.2022.05.003
Signorelli M, Guerra L, Pirovano C, Crivellaro C, Fruscio R, Buda A, et al. Detection of nodal metastases by FDG PET-CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol 2013:131:395-9
DOI: 10.1016/j.ygyno.2013.08.022
Ghosh J, Thulkar S, Kumar R, Malhotra A, Kumar A, Kumar L. Role of FDG PET-CT in aymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study. Natl Med J India 2013;26:327-31.
Picchio M, Sironi S, Messa C, Mangili G, Landoni C, Gianolli L, et al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med 2003;47(2):77-84.
Kyriazi S, Collins DJ, Messiou C, Pennert K, Davidson RL, Giles SL, et al. Metastatic ovarian and primary peritoneal cancer: Assessing chemotherapy response with diffusion-weighted MR imaging-value of histogram analysis of apparent diffusion coefficients. Radiology 2011;261(1):182-92.
DOI: 10.1148/radiol.11110577
Sala E, Kataoka MY, Priest AN, Gill AB, McLean MA, Joubert I, et al. Advanced ovarian cancer: Multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology 2012;263(1):149-59.
DOI: 10.1148/radiol.11110175
Winfield JM, Wakefield JC, Dolling D, Hall M, Freeman S, Brenton JD, et al. Diffusion-weighted MRI in advanced epithelial ovarian cancer: Apparent diffusion coefficient as a response marker. Radiology 2019;293(2):374-83.
DOI: 10.1148/radiol.2019190545
Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92(9):1599-610.
DOI: 10.1038/sj.bjc.6602550
Chilla B, Hauser N, Singer G, Trippel M, Froehlich JM, Kubik-Huch RA. Indeterminate adnexal masses at ultrasound: Effect of MRI imaging findings on diagnostic thinking and therapeutic decisions. Eur Radiol 2011;21(6):1301-10.
DOI: 10.1007/s00330-010-2018-x
Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PETCT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009;71:164-74.
DOI: 10.1016/j.ejrad.2008.02.019
Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. Cancer Discov 2021;11(4):900-15.
DOI: 10.1158/2159-8290.CD-21-0090
Sadeghi MH, Sina S, Omidi H, Farshchitabrizi AH, Alavi M. Deep learning in ovarian cancer diagnosis: a comprehensive review of various imaging modalities. Pol J Radiol 2024;89:30-48.
DOI: 10.5114/pjr.2024.134817
Wang M, Perucho JAU, Hu Y, Choi MH, Han L, Wong EMF, et al. Computed tomographic radiomics in differentiating histologic subtypes of epithelial ovarian carcinoma. JAMA Netw Open 2022;5(12):e2245141.
DOI: 10.1001/jamanetworkopen.2022.45141
Hatamikia S, Nougaret S, Panico C, Avesani G, Nero C, Boldrini L, et al. Ovarian cancer beyond imaging: Integration of AI and multiomics biomarkers. Eur Radiol Exp 2023;7:50.
DOI: 10.1186/s41747-023-00364-7

Artículos más populares


Editado en Madrid por:
Diseño y Desarrollo web Im3diA comunicación

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Más información en el apartado “POLÍTICA DE COOKIES” de nuestra página web.

Rechazar